Saltar al contenido
Merck

Comparison of sequential and 7-, 10-, 14-d triple therapy for Helicobacter pylori infection.

World journal of gastroenterology (2012-06-02)
Hyuk Soon Choi, Hoon Jai Chun, Sang Hoon Park, Bora Keum, Yeon Seok Seo, Yong Sik Kim, Yoon-Tae Jeen, Soon Ho Um, Hong Sik Lee, Chang Duck Kim, Ho Sang Ryu
RESUMEN

To compare the effectiveness of sequential therapy for Helicobacter pylori (H. pylori) infection with that of triple therapy of varying durations. The 460 patients enrolled in this study had H. pylori-associated gastritis or a gastric or duodenal ulcer. After screening, H. pylori-infected patients were randomly assigned to receive either conventional triple therapy for 7, 10 or 14 d, or a new 10-d sequential therapy. Each of the 4 treatment groups included 115 patients. The outcomes of eradication therapy were assessed 4 wk after treatment by the urea breath test and histology. The overall eradication rate was 81.0%, and eradication rates were 75.7% for 7-d conventional triple therapy, 81.9% for 10-d conventional triple therapy, 84.4% for 14-d conventional triple therapy, and 82.0% for 10-d sequential therapy. Neither intention-to-treat analysis nor per protocol analysis showed significant differences in eradication rates using sequential therapy or the standard triple therapy (P = 0.416 and P = 0.405, respectively). There are no significant differences between 10-d sequential eradication therapy for H. pylori and any duration of standard triple treatment in Korean patients.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Supelco
Tinidazole, VETRANAL®, analytical standard